Vaginal atrophy is common in postmenopausal women. This clinical guide provides the evidence for the clinical use of vaginal estrogens for this condition focussing on publications since the 2006 Cochrane systematic review. Use after breast cancer, before assessment of cervical cytology and prolapse surgery is also discussed. (C) 2012 Elsevier Ireland Ltd. All rights reserved
Due to the increase in life expectancy, today, most women live in a state of estrogen deficiency for...
SA Kingsberg¹, S Kellogg², M Krychman³1University Hospitals Case Medical ...
Objectives:To evaluate efficacy and safety of low-dose conjugated estrogen cream (0.3 mg) for treatm...
Introduction: Vulvovaginal atrophy (VVA) is a chronic condition caused by estrogen deficiency. It af...
Osteoporosis and the resulting fractures are major public health issues as the world population is a...
Postmenopausal vaginal atrophy: evaluation of treatment with local estrogen therap
Osteoporosis and the resulting fractures are major public health issues as the world population is a...
OBJECTIVE: To update and expand the previous position statement of The North American Menopause Soci...
Early menopause and related vaginal atrophy is a well known side-effect of hormone adjuvant treatmen...
Unlike hot flushes and night sweats which resolve spontaneously in time, atrophic symptoms affecting...
The British Menopause Society Council aims to aid health professionals in providing up to date and i...
Mary Jane Minkin,1 Ricardo Maamari,2 Suzanne Reiter3 1Department of Gynecology and Reproductive Medi...
This new statement from EMAS presents the findings reported in recent publications from both WHI and...
Hormone therapy is still the most commonly used treatment to relieve menopausal symptoms and the con...
PURPOSE OF INVESTIGATION: To verify the effectiveness and safety of low-dose 17beta-estradiol vagina...
Due to the increase in life expectancy, today, most women live in a state of estrogen deficiency for...
SA Kingsberg¹, S Kellogg², M Krychman³1University Hospitals Case Medical ...
Objectives:To evaluate efficacy and safety of low-dose conjugated estrogen cream (0.3 mg) for treatm...
Introduction: Vulvovaginal atrophy (VVA) is a chronic condition caused by estrogen deficiency. It af...
Osteoporosis and the resulting fractures are major public health issues as the world population is a...
Postmenopausal vaginal atrophy: evaluation of treatment with local estrogen therap
Osteoporosis and the resulting fractures are major public health issues as the world population is a...
OBJECTIVE: To update and expand the previous position statement of The North American Menopause Soci...
Early menopause and related vaginal atrophy is a well known side-effect of hormone adjuvant treatmen...
Unlike hot flushes and night sweats which resolve spontaneously in time, atrophic symptoms affecting...
The British Menopause Society Council aims to aid health professionals in providing up to date and i...
Mary Jane Minkin,1 Ricardo Maamari,2 Suzanne Reiter3 1Department of Gynecology and Reproductive Medi...
This new statement from EMAS presents the findings reported in recent publications from both WHI and...
Hormone therapy is still the most commonly used treatment to relieve menopausal symptoms and the con...
PURPOSE OF INVESTIGATION: To verify the effectiveness and safety of low-dose 17beta-estradiol vagina...
Due to the increase in life expectancy, today, most women live in a state of estrogen deficiency for...
SA Kingsberg¹, S Kellogg², M Krychman³1University Hospitals Case Medical ...
Objectives:To evaluate efficacy and safety of low-dose conjugated estrogen cream (0.3 mg) for treatm...